

Curriculum Vitae

Personal information **Frederika Vermeij-van Nimwegen**

Work experience

- Oct 2023 - Present **Assessor Pharmacovigilance**, Medicines Evaluation Board, Department of Pharmacovigilance (NL)
- Assessing the safety of new and existing medicinal products and their pharmacovigilance in the field of oncology, haematology, pulmonology, immunology, anti-emetics, allergens, medicinal gasses and antitussives. This includes the assessment of Risk Management Plans, Periodic Safety Update Reports, assessment of the Summary of Product Characteristics, signals, Post-Authorization Safety Study protocols and results, risk minimization materials and Direct Healthcare Professional Communications.
- Sep 2022 - Aug 2023 **Senior Epidemiologist**, P95 (BE)
- Provided advice on the execution of epidemiological studies for the COVIDRIVE consortium, specifically for Novavax's and Valneva's studies on the effectiveness of their COVID-19 vaccines against hospitalization in the real-world setting. Provided lectures to the pharmacovigilance department on writing of RMPs, and to the epidemiology department on the EU regulatory system.
- Oct 2015 - Aug 2022 **Assessor Pharmacovigilance**, Medicines Evaluation Board, Department of Pharmacovigilance (NL).
- Assessing the safety of new and existing medicinal products and their pharmacovigilance in the field of oncology, haematology, pulmonology, immunology, anti-emetics, allergens, medicinal gasses and antitussives. This includes the assessment of Risk Management Plans, Periodic Safety Update Reports, assessment of the Summary of Product Characteristics, signals, Post-Authorization Safety Study protocols and results, risk minimization materials and Direct Healthcare Professional Communications.
- Nov 2010 - Nov 2015 **PhD candidate**, Netherlands Cancer Institute, Department of Epidemiology, and VU University Amsterdam (NL).
- Dissertation: 'Risk of Cardiovascular Diseases after Hodgkin Lymphoma Treatment'. Data collection, coordination, analysis and publication of several epidemiological projects including case-control studies, cohort studies, patient questionnaires and data collection. Managing 2 to 6 research assistants, supervising interns. Presenting and communicating scientific study results to peers and layman.

Education and training

- Oct 2010 - Oct 2015 PhD candidate, VU University Amsterdam (NL)
- Sep 2009 - Jul 2010 MSc. Epidemiology, Maastricht University (NL)
- Sep 2008 - Jul 2009 MSc. Infectious Diseases and Public Health, VU University Amsterdam (NL)
- Sep 2005 - Jul 2008 BSc. Health Sciences, VU University Amsterdam (NL)
- Sep 1999 - Jul 2005 Pre-University Education, Kaj Munk College (NL)

Additional information

Publications

- A. van Haren, **R Vermeij-van Nimwegen**, J. James, et al. UNICOM working paper - IDMP Coding Principles and Guidance for ICSRs. 30 Sept 2022.
- S de Vries S, M Schaapveld M, **FA van Nimwegen**, et al. High burden of subsequent malignant neoplasms and cardiovascular disease in long-term Hodgkin lymphoma survivors. *British Journal of Cancer* 2018;118(6):887-895
- FA van Nimwegen**, et al. Risk of heart failure in survivors of Hodgkin lymphoma: effects of cardiac exposure to radiation and anthracyclines. *Blood* 2017;129(16):2257-2265
- FA van Nimwegen**, et al. Reply to D. Vordermark and T. Pelz and R. Mazzola et al. *Journal of Clinical Oncology* 2016;34(24):2941-2942
- FA van Nimwegen**, et al. Radiation Dose-Response Relationship for Risk of Coronary Heart Disease in Survivors of Hodgkin Lymphoma. *Journal of Clinical Oncology* 2016;24(3):235-243
- FA van Nimwegen**, et al. Cardiovascular Disease After Hodgkin Lymphoma

Treatment: 40-Year Disease Risk. JAMA Internal Medicine
2015;175(6):1007-1017

FA van Nimwegen, et al. Simple Methods to Estimate Mean Heart Dose From
Hodgkin Lymphoma Radiation Therapy According to Simulation X-rays.
International Journal of Radiation Oncology*Biological*Physics
2015;92(1):153-160

DC Cutter, M Schaapveld, SC Darby, M Hauptmann, **FA van Nimwegen**, et al.
Risk of Valvular Heart Disease After Treatment for Hodgkin Lymphoma.
Journal of the National Cancer Institute 2015;107(4):djv008

FA van Nimwegen, et al. Risk of diabetes mellitus in long-term survivors of
Hodgkin lymphoma. Journal of Clinical Oncology 2014;32(29):3257-3263

FA van Nimwegen, et al. Mode and place of delivery, gastrointestinal
microbiota, and their influence on asthma and atopy. Journal of Allergy
and Clinical Immunology 2011;128(5):948-955.e3

Projects

UNICOM project – Deliverable D8.7: IDMP Coding Principles and Guidance for ICSRs ([Home - UNICOM \(unicom-project.eu\)](http://home-unicom-project.eu))

Memberships

Other Relevant Information